Clinical Trials Logo

Phase II Clinical Trial clinical trials

View clinical trials related to Phase II Clinical Trial.

Filter by:
  • None
  • Page 1

NCT ID: NCT04338867 Completed - Clinical trials for Ninety-six Histologically Confirmed NSCLC Patients With BM

Nitroglycerin Plus Intracranial Radiotherapy for Brain Metastases in NSCLC Patients

Start date: March 1, 2020
Phase: Phase 2
Study type: Interventional

Background: Whole-brain radiotherapy (WBRT) is the standard treatment for multiple brain metastases (BM), in NSCLC patients who are not candidates for treatment with stereotactic radiation body therapy. Hypoxia has been associated with chemo-radioresistance secondary to Vascular Endothelial Growth Factor Receptor (VEGFR) induced by Hypoxia Induced Factor (HIF). Nitroglycerin (NTG) can reduce HIF-1 alfa in tissues, and this may have anti-angiogenic, pro-apoptotic and anti-efflux effects. In this phase II study, we evaluated the effect of transdermal nitroglycerin (TN) on intracranial progression-free survival (ICPFS), objective response rate (ORR) and overall survival (OS) of NSCLC patients with BM. Material and methods: We performed an open-label, phase II clinical trial among ninety-six histologically confirmed NSCLC patients with BM. Patients were randomized 1:1 to receive NTG plus WBRT or WBRT alone. ORR and ICPFS were evaluated by MRI by two independent, blinded radio-oncologists.